CITCCA data demonstrate more than 40% of high-risk stage I–III colorectal patients harbor molecular residual disease at clinical landmark, detectable only with ultrasensitive ctDNA testing.
AI, new diagnostics, and shifting care delivery models are among the clinical laboratory predictions for 2026.
New recommendations address evolving drug landscape and advancing testing technologies since original 2003 guidance.
The collaboration aims to unify data systems and automate workflows across pathology laboratories to address operational challenges.
Special issue explores advances in noninvasive prenatal screening, molecular diagnostics, and care disparities affecting perinatal outcomes.
